Clinical trials: Estrogen Therapy
Hypoactive Sexual Desire Disorder
Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen
The purpose of this study is to examine whether the transdermal testosterone system (TTS) is effective and safe in the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women who are on transdermal estrogen.
- Trial name
- NCT00384046
- Testing
- Testosterone
- Where
- 31 sites in Australia, Botswana and 3 more
- Volunteers
- 272 people
- Sponsor
- Warner Chilcott
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Biology Guided Therapy for Breast Cancer for ER Positive
There are several approved and guideline-recommended treatments for metastatic, estrogen receptor-positive breast cancer that has progressed on an aromatase inhibitor and a CDK4/6 inhibitor.
- Conditions
- Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- SPOCK (NCT04965688)
- Testing
- Biopsy-Guided Therapy Selection
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Inova Health Care Services
Breast Cancer
Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Anastrozole may fight breast cancer by blocking the production of estrogen by the tumor cells.
- Trial name
- NCT00049062
- Testing
- anastrozole, gefitinib
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Urinary Bladder, Overactive, Effect of Drug
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.
- Trial name
- NCT06197295
- Testing
- Solifenacin with vaginal estrogen cream, Combination pharmacotherapy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Mackay Memorial Hospital
Transsexualism, Transgenderism
Effects of Cross-sex Hormone Therapy on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System
Current study aims to characterize five highly interconnected physiological systems in patients undergoing cross-sex hormone therapy - namely glucose and lipid metabolism, energy balance, eating behavior, functional brain…
- Conditions
- Transsexualism, Transgenderism, Adiposity, Eating Behavior
- Trial name
- HHS (NCT04838249)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Leipzig
Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
This phase Ib trial studies the best dose of berzosertib when given together with the usual treatment (radiation therapy) in treating patients with triple negative or estrogen receptor and/or progesterone receptor positive, HER-2…
- Conditions
- Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04052555
- Testing
- Berzosertib, Biospecimen Collection, Quality-of-Life Assessment
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Metastatic Breast Cancer
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer
- Trial name
- EVOLVE-BDT (NCT07340541)
- Testing
- SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine
- Where
- 6 sites in United States
- Volunteers
- 700 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Breast Cancer, Breast Carcinoma
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have progressed on an aromatase inhibitor plus a CDK4/6 inhibitor…
- Trial name
- MAINTAIN (NCT02632045)
- Testing
- LEE-011, Fulvestrant
- Where
- 13 sites in United States
- Volunteers
- 169 people
- Sponsor
- Melissa K Accordino
Breast Cancer, Estrogen Receptor Positive Breast Cancer
A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
The purpose of this research study is to evaluate a decision aid to help women aged 70 and older decide on treatment for their breast cancer.
- Conditions
- Breast Cancer, Estrogen Receptor Positive Breast Cancer, Node-negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- NCT02823262
- Testing
- Breast Cancer Treatment Decision Aid for women 70+, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Beth Israel Deaconess Medical Center
Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom.
- Trial name
- NCT06450873
- Testing
- Coriolus Versicolor Extract, Questionnaire Administration
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Breast Cancer, Arthralgia
Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms
Early stage hormone receptor positive breast cancer is typically treated with adjuvant endocrine therapy in order to decrease risk of breast cancer recurrence and to improve overall survival from the disease.
- Trial name
- NCT02118636
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Lynn Henry
Breast Cancer
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a…
- Trial name
- CONFIRM (NCT00099437)
- Testing
- Fulvestrant
- Where
- 106 sites in United States, Belgium and 15 more
- Volunteers
- 736 people
- Sponsor
- AstraZeneca
Infertility, Ovarian Failure, Premature
Maturation of Follicles After Transplantation of Ovarian Tissue Into the Pelvic Wall and the Ovary
The purpose of this study is to determine whether the pelvic wall or the ovary represents a better location for the maturation of follicles in the context of ovarian transplantation after cryopreservation of ovarian tissue before…
- Trial name
- Ovartrans (NCT02780791)
- Testing
- Transplantation into pelvic wall, Transplantation into the ovary
- Where
- Switzerland
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Venous Thrombosis, Insulin Resistance
Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy
Ultra-low-dose oral E2/D will have more beneficial effects than trans-dermal HRT on lipids and insulin resistance in postmenopausal women, whilst adverse effects on coagulation will be avoided.
- Trial name
- OPTIMISE (NCT02264743)
- Testing
- Femoston Conti, EVOREL® CONTI
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Contraception
A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles
Investigation of a new pill containing an estrogen and a progestin in order to monitor the inhibition of the ovulation in young healthy females over 3 treatment cycles
- Trial name
- NCT00631124
- Testing
- BAY86-4891 (Estradiol / Drospirenone)
- Where
- 2 sites in Germany
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Bayer
Estrogen Receptor Positive, HER2/Neu Negative
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- NCT01928186
- Testing
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Recurrent Urinary Tract Infection, Hypoestrogenism
Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections
The goal of this clinical trial is to learn about medication adherence to difference types of vaginal estrogen in women with low levels of estrogen (for example, post-menopausal women) who have recurrent urinary tract infections.
- Trial name
- NCT06353269
- Testing
- Estring Vaginal Product, Vagifem, Estrace 0.01% Vaginal Cream
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Breast Cancer
Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial
Purpose: This study aimed to analyze changes in serum estradiol (E2) levels during concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast cancer (BC) patients with vulvovaginal atrophy (VVA).
- Trial name
- NCT06654570
- Testing
- Intravaginal estrogen during adjuvant letrozole
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Helsinki University Central Hospital
Metastatic Breast Cancer
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor [Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)].
- Trial name
- VERU-024 (NCT05065411)
- Testing
- Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
- Where
- 30 sites in United States
- Volunteers
- 5 people
- Sponsor
- Veru Inc.
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
This trial studies how well a text-based intervention works in improving adherence to hormone therapy in patients with stage I-III hormone receptor positive breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04086875
- Testing
- Focus Group, Text Message, Best Practice
- Where
- 7 sites in United States
- Volunteers
- 332 people
- Sponsor
- Thomas Jefferson University